Clinical Trials

Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)

• Condition: Prostatic Neoplasms
• Intervention: Biological: Pembrolizumab 200 mg, Drug: Olaparib 400 mg, Drug: Docetaxel 75 mg/m^2, Drug: Prednisone 5 mg, Drug: Enzalutamide 160 mg, Other: Dexamethasone 8 mg
• Study ID: NCT02861573

Development of Tissue Predictors of Abiraterone Benefit in Men With mCRPC

• Condition: Metastatic Castration-resistant Prostate Cancer
• Intervention:
• Study ID: NCT03176381

Cognitive Effects of Androgen Receptor (AR) Directed Therapies for Advanced Prostate Cancer

• Condition: Castration-Resistant Prostatic Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer, Hormone-Refractory Prostate Cancer
• Intervention: Biological: GnRH agonist/antagonist, Drug: Prednisone, Drug: Abiraterone Acetate, Drug: Enzalutamide
• Study ID: NCT03016741

Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer

• Condition: Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
• Intervention: Drug: Abiraterone, Drug: Bicalutamide, Drug: Degarelix, Drug: Docetaxel, Drug: Flutamide, Drug: Goserelin Acetate, Drug: Histrelin Acetate, Drug: Leuprolide Acetate, Drug: Nilutamide, Procedure: Orchiectomy, Drug: Prednisone, Other: Quality-of-Life Assessment, Radiation: Radiation Therapy, Procedure: Radical Prostatectomy, Drug: Triptorelin
• Study ID: NCT03678025

Cytoreductive Prostatectomy Versus Cytoreductive Prostate Irradiation as a Local Treatment Option for Metastatic Prostate Cancer: a Multicentric Feasibility Trial

• Condition: Prostate Cancer Metastatic
• Intervention:
• Study ID: NCT03655886

High Dose Testosterone in Men With Advanced Prostate Cancer and Homologous Recombination Deficiency

• Condition: Castration-resistant Prostate Cancer, Homologous Recombination Deficiency
• Intervention: Drug: Testosterone Enanthate
• Study ID: NCT03522064

Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

• Condition: Prostate Cancer
• Intervention: Drug: Docetaxel 75 mg/m2, Drug: Docetaxel 60 mg/m2, Drug: Radium-223
• Study ID: NCT03574571

Randomized, Multicentre Phase II Trial of the Sequencing of Radium-223 and Docetaxel Plus Prednisone in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer (mCRPC)

• Condition: Metastatic Castration-resistant Prostate Cancer
• Intervention:
• Study ID: NCT03230734

177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer

• Condition: Metastatic Castration Resistant Prostate Cancer (mCRPC)
• Intervention:
• Study ID: NCT03874884

A Phase 1/2 Study of Combination Olaparib and Radium-223 in Men With Metastatic Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE)

• Condition: Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Carcinoma Metastatic in the Bone, PSA Level Greater Than or Equal to Two, PSA Progression
• Intervention: Other: Laboratory Biomarker Analysis, Drug: Olaparib, Radiation: Radium Ra 223 Dichloride
• Study ID: NCT03317392

Ice-CAP: A Phase I Trial of Ipatasertib in Combination With Atezolizumab in Patients With Advanced Solid Tumours With PI3K Pathway Hyperactivation

• Condition: Solid Tumor, Glioblastoma Multiforme, Prostate Cancer Metastatic
• Intervention: Drug: ipatasertib, Drug: Atezolizumab
• Study ID: NCT03673787

A Phase 2 Study of a Checkpoint Inhibitor in Men With Progressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation

• Condition: Metastatic Castration Resistant Prostate Cancer
• Intervention: Drug: Pembrolizumab
• Study ID: NCT04104893

Phase II Trial of pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer

• Condition: Castration-resistant Prostate Cancer, Metastatic Cancer, Prostate Cancer
• Intervention: Biological: pTVG-HP, Biological: pTVG-AR, Drug: Pembrolizumab, Drug: rhGM-CSF
• Study ID: NCT04090528

ProBio: An Outcome-adaptive and Randomized Multi-arm Biomarker Driven Study in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

• Condition: Metastatic Castration-Resistant Prostatic Cancer
• Intervention: Drug: Enzalutamide Oral Capsule [Xtandi], Drug: Abiraterone Oral Tablet [Zytiga], Drug: Carboplatin, Drug: Cabazitaxel 60 mg Solution for Injection, Drug: Docetaxel Injectable Solution, Drug: Radium Chloride Ra-223
• Study ID: NCT03903835

An Extended/Phase 2, Multi-Center, Randomized, Open-Label Study to Evaluate the Safety and Tolerability of GT0918 in Subjects With Metastatic Castrate Resistant Prostate Cancer (mCRPC) Who Failed Either Abiraterone or Enzalutamide

• Condition: Metastatic Castrate Resistant Prostate Cancer (mCRPC)
• Intervention: Drug: GT0918
• Study ID: NCT03899467

A Phase 3, Randomized, Double-Blind Study of Nivolumab or Placebo in Combination With Docetaxel, in Men With Metastatic Castration-resistant Prostate Cancer

• Condition: Prostate Cancer
• Intervention: Biological: nivolumab, Drug: prednisone, Drug: docetaxel
• Study ID: NCT04100018

A Phase I Study to Evaluate PSCA-Targeting Chimeric Antigen Receptor (CAR)-T Cells for Patients With Metastatic Castration Resistant Prostate Cancer

• Condition: Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, PSA Progression, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, PSCA Positive
• Intervention: Biological: Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes, Drug: Cyclophosphamide, Drug: Fludarabine, Drug: Fludarabine Phosphate
• Study ID: NCT03873805

A Phase I Trial of Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer (CRPC)

• Condition: Metastatic Castrate Resistant Prostate Cancer
• Intervention: Drug: Docetaxel, Radiation: Radium 223
• Study ID: NCT03737370

A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer

• Condition: Metastatic Castration-resistant Prostate Cancer
• Intervention: Drug: REGN5678, Drug: Cemiplimab
• Study ID: NCT03972657

A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Re

• Condition: Metastatic Castrate Sensitive Prostate Cancer
• Study ID: NCT04497844

A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination With Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects With Metastatic Castration-Resistant Prostate Cancer

• Condition: Metastatic Prostate Cancer, Prostate Adenocarcinoma
• Study ID: NCT04446117

A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib+Abiraterone Versus Placebo+Abiraterone as Treatment for Patients With DeNovo Metastatic Hormone-Sensitive Prostate Cancer Characterised by PTE

• Condition: Hormone-Sensitive Prostate Cancer
• Study ID: NCT04493853

Prostate Cancer Biomarker Enrichment and Treatment Selection (PC-BETS) Study

• Condition: Prostate Cancer
• Intervention: Drug: AZD1775, Drug: Savolitinib, Drug: Darolutamide
• Study ID: NCT03385655

A Study to Evaluate the Safety and Efficacy of IMMU-132 (Sacituzumab Govitecan) in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Progressed on Second Generation AR-Directed Therapy

• Condition: Prostate Cancer
• Intervention: Drug: IMMU-132
• Study ID: NCT03725761

Phase I/II Dose-escalation Study of Fractionated and Multiple Dose 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer

• Condition: Prostate Cancer
• Study ID: NCT04506567

ENZA-p: A Randomised Phase II Trial Using PSMA as a Therapeutic Agent and Prognostic Indicator in Men With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide

• Condition: Metastatic Castration-Resistant Prostate Cancer
• Study ID: NCT04419402

A Phase 3, Open-Label, Randomized Study Evaluating Metastatic Castrate Resistant Prostate Cancer Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment (SPLASH)

• Condition: Metastatic Castration-Resistant Prostate Cancer
• Study ID: NCT04647526

A Randomized Phase II Study of 177 LuPSMA-617 vs Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer and PSMA-Positive Disease

• Condition: Prostate Cancer
• Study ID: NCT04663997

UpFrontPSMA : A Randomised Phase 2 Study of Sequential 177Lu-PSMA617 and Docetaxel Versus Docetaxel in Metastatic Hormone-Naive Prostate Cancer

• Condition: Metastatic Hormone Naive Prostate Cancer
• Study ID: NCT04343885

Early Detection of Prostate Cancer by Liquid Biopsy

• Condition: Prostate Cancer
• Study ID: NCT04556916

A Phase 1, Open-label Study in Two Parts, Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of CCW702 in Patients With Metastatic, Castration Resistant Prostate Adenocarcinoma

• Condition: Castration-Resistant Prostatic Cancer
• Intervention: Drug: CCW702
• Study ID: NCT04077021

• Condition: Prostate Cancer
• Study ID: NCT04390880

A Phase II Multi-Center Trial of Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer

• Condition: Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
• Study ID: NCT04751929

Local Cytoreductive Treatments for Men With Newly Diagnosed Metastatic Prostate Cancer in Addition to Standard of Care Treatment

• Condition: Prostate Cancer, Metastatic Prostate Cancer
• Intervention: Combination Product: Standard of Care, Procedure: Minimally Invasive Ablative Therapy (MIAT), Procedure: Radical Therapy (Prostatectomy or Radiotherapy)
• Study ID: NCT03763253

A Phase IIA Study of Sequential ("First Strike, Second Strike") Therapies, Modeled on Evolutionary Dynamics of Anthropocene Extinctions, for High Risk Metastatic Castration Sensitive Prostate Cancer

• Condition: Prostate Cancer, Stage IV Prostate Cancer
• Study ID: NCT05189457

Phase I/II 225Ac-J591 Plus 177Lu-PSMA-I&T for Progressive Metastatic Castration Resistant Prostate Cancer

• Condition: Prostate Cancer
• Study ID: NCT04886986

A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of 177Lu-PSMA-I&T Versus Hormone Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

• Condition: Metastasis From Malignant Tumor of Prostate
• Study ID: NCT05204927

A Multi-Center, Open-Label, Randomized Phase 2 Study of Copper Cu 64 PSMA I&T Injection in Patients With Histologically Proven Metastatic Prostate Cancer

• Condition: Metastasis From Malignant Tumor of Prostate (Disorder)
• Study ID: NCT05653856

A Phase 2, Open-label, Randomized Controlled Trial of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer

• Condition: Prostatic Neoplasms, Castration-Resistant
• Study ID: NCT05169684